The 8th edition of the TNM classification of lung cancers has been in effect since 2017. These recommendations have been summarized in publications issued by the Union for International Cancer Control (UICC), the American Joint Committee on Cancer (AJCC), and the International Association for the Study of Lung Cancer (IASLC).
Surgery in the form of maximum cytoreduction is recommended to reduce all visible disease in the setting of resectable malignant pleural mesothelioma. Extra-pleural pleurectomy/decortication has been established as the predominant approach offered worldwide.
Immune checkpoint inhibitor-based regimens have been established as the standard-of-care first-line treatment in the setting of metastatic NSCLC. However, novel combination approaches are called for to further improve outcomes.
Improving long-term survival remains an unmet need in the setting of extensive-stage small-cell lung cancer (ES-SCLC). This might be attributed at least in part to the complexity of the tumor microenvironment, which is characterized by immunosuppression, angiogenesis and vascularization.
In the first-line setting of EGFR-mutant advanced NSCLC, EGFR tyrosine kinase inhibitors (TKIs) such as the third-generation agent osimertinib have been established as the standard of care, although treatment is followed by disease progression in most patients. Data on the combined administration of EGFR TKIs with chemotherapy suggest enhanced efficacy.
Given the high incidence and mortality rates of lung cancer in Taiwan and the established association between survival and disease stage at diagnosis, the Taiwanese national early detection program for lung cancer was launched in July 2022 with the aim of increasing the proportion of tumors identified at an early stage using low-dose CT (LDCT).
The International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) was held in Singapore and virtually from 9th to 12th September. This prestigious event served as a global gathering point uniting over 6,000 renowned international scientists, researchers, and devoted patient advocates.
